The Evidence
Most supplements are designed for the general wellness shelf. OncoCare™ is designed for a specific moment in cancer care. Every formula is interaction-aware , each ingredient is cross-referenced against the metabolic profile of the antibody-drug conjugate it accompanies , and indication-specific, with doses drawn from peer-reviewed research in the relevant ovarian and breast cancer populations. We don't add an ingredient unless the evidence and the timing both make sense.
Our Clinical Standard
How we make sure every supplement is safe to take alongside your chemotherapy
Think of your liver as a security checkpoint at an airport. Every substance that enters your body , drugs, supplements, even some foods , has to pass through this checkpoint before it can do its job or get cleared out of your system.
CYP3A4 is the name of the most important security officer at that checkpoint. It is an enzyme in your liver that processes roughly half of all medications humans take , including the chemotherapy drugs used in ELAHERE and ENHERTU treatment.
Some supplements are like cutting in line at that checkpoint. They overwhelm the CYP3A4 enzyme and slow it down. When that happens, your chemotherapy cannot be processed at the right speed. It builds up in the bloodstream at higher levels than intended, which increases side effects and toxicity. Other supplements do the opposite , they speed the checkpoint up so fast that your chemo gets cleared out of the body before it has a chance to work. Either way, the drug does not perform the way your oncologist designed it to.
Every ingredient in an OncoCare formulation has been checked against that checkpoint before it enters any product we make.
We only include supplements that pass through a different line entirely , ones that have no meaningful interaction with CYP3A4 at therapeutic doses.
That way your chemotherapy drug works exactly the way your oncologist intended. Your supplements do their job. Neither gets in the way of the other.
This is not something general wellness brands do. It is the entire reason OncoCare exists.
| Supplement | What It Does to the Checkpoint | The Risk |
|---|---|---|
| High-dose Curcumin | Slows it down (inhibitor) | Chemo builds up , increased toxicity |
| St. John's Wort | Speeds it up (inducer) | Chemo clears too fast , reduced effectiveness |
| Grapefruit | Slows it down strongly | Can reach dangerous drug levels in bloodstream |
| High-dose EGCG (green tea extract) | Slows it down | Same risk as curcumin at high doses |
| High-dose Berberine | Slows it down | Elevated chemo concentration risk |
| Alpha Lipoic Acid | Liver processing burden | Competes during active treatment cycles |
All of the above are commonly recommended in general wellness and even some integrative oncology contexts. OncoCare excludes them from active treatment formulations specifically because of these interactions , not because they are bad supplements, but because the timing is wrong.
Each core ingredient, what it does, the research that informs it, and why it's dosed the way it is.
Active hexose correlated compound, a cultured shiitake mycelia extract that supports natural killer cell activity and immune resilience during cytotoxic therapy.
Key study
Smith et al., Journal of Nutrition (2019): AHCC supplementation increased NK cell activity in patients undergoing chemotherapy.
Dosing rationale
Dosed at 3 g/day in line with peer-reviewed oncology protocols, taken away from ADC infusion windows to avoid metabolic interference.
Supports bone integrity, calcium handling, and immune modulation , frequently depleted in patients on long-cycle treatment.
Key study
Manson et al., NEJM (2019): vitamin D supplementation associated with reduced cancer mortality in long-term follow-up.
Dosing rationale
2,000 IU D3 with 90 mcg K2 (MK-7) to direct calcium to bone and away from soft tissue, dosed for daily maintenance.
High-purity marine omega-3s that help balance the inflammatory response and support lean body mass during treatment.
Key study
Murphy et al., Cancer (2011): omega-3 supplementation helped maintain muscle mass in patients receiving chemotherapy.
Dosing rationale
2 g combined EPA+DHA daily, molecularly distilled for purity and screened against ADC metabolism.
Circadian and sleep support with antioxidant properties; included in evening formulas to aid recovery without daytime sedation.
Key study
Seely et al., Integrative Cancer Therapies (2012): melatonin associated with improved outcomes and tolerability alongside oncology care.
Dosing rationale
3 mg in the PM formula, timed at night to align with circadian rhythm and minimize interaction with daytime therapy.
A galectin-3 modulating fiber researched primarily in ovarian and solid-tumor contexts for its role in cellular adhesion signaling.
Key study
Eliaz et al., Clinical Medicine Insights (2019): modified citrus pectin showed galectin-3 inhibition in clinical evaluation.
Dosing rationale
5 g/day, formulated specifically for ELAHERE patients based on the ovarian indication evidence base.
Hepatoprotective flavonolignan complex that supports liver function during the metabolic load of ADC therapy.
Key study
Ladas et al., Cancer (2010): silymarin reduced markers of hepatotoxicity in patients on chemotherapy.
Dosing rationale
200 mg standardized silymarin, screened for CYP interactions and timed away from infusion days.
Highly bioavailable, gentle magnesium that supports muscle relaxation, sleep quality, and neuromuscular comfort.
Key study
Castiglioni et al., Nutrients (2013): magnesium status linked to neuromuscular function and recovery.
Dosing rationale
150 mg elemental magnesium in the PM formula , the glycinate form chosen to avoid GI upset common with oxide salts.
A glutathione precursor supporting the body's primary antioxidant defense and respiratory mucosal health.
Key study
Pendyala & Creaven, Cancer Epidemiology (1995): NAC raised intracellular glutathione in human supplementation trials.
Dosing rationale
600 mg/day, dosed in the morning and screened for timing relative to ADC mechanism of action.
A broccoli-derived Nrf2 activator that upregulates the body's endogenous detoxification and antioxidant pathways.
Key study
Atwell et al., Molecular Nutrition & Food Research (2015): sulforaphane modulated Nrf2 pathway activity in clinical evaluation.
Dosing rationale
Standardized to deliver active sulforaphane in the AM formula, supporting daytime cellular defense.
The reduced, readily absorbed form of CoQ10 supporting mitochondrial energy production and cardiac resilience.
Key study
Mortensen et al., JACC Heart Failure (2014): CoQ10 supplementation supported cardiac function in controlled trials.
Dosing rationale
100 mg ubiquinol daily, particularly relevant where treatment carries cardiac monitoring considerations.
A flavonoid with antioxidant and mast-cell stabilizing properties, included to support GI comfort on HER2-directed therapy.
Key study
Li et al., Nutrients (2016): quercetin demonstrated anti-inflammatory and antioxidant effects in clinical settings.
Dosing rationale
250 mg/day, formulated into the ENHERTU protocol and screened against trastuzumab deruxtecan metabolism.
Standardized gingerol extract clinically studied for nausea relief , targeted to the GI side-effect profile of ENHERTU.
Key study
Ryan et al., Supportive Care in Cancer (2012): ginger reduced chemotherapy-induced nausea in a randomized trial.
Dosing rationale
1 g standardized extract, included in the ENHERTU GI support formula for daily symptom management.
Citations are provided for educational purposes and do not imply that these products treat, cure, or prevent cancer. Always review any supplement with your oncology care team before starting.
Choose the protocol matched to your therapy and care team's guidance.